These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
150 related articles for article (PubMed ID: 23463206)
1. Hepatitis C virus-specific directly acting antiviral drugs. Delang L; Neyts J; Vliegen I; Abrignani S; Neddermann P; De Francesco R Curr Top Microbiol Immunol; 2013; 369():289-320. PubMed ID: 23463206 [TBL] [Abstract][Full Text] [Related]
2. Understanding the molecular targets for new therapeutical agents in hepatitis c infection. Vagu C; Sultana C; Ruţă S Roum Arch Microbiol Immunol; 2013; 72(1):5-24. PubMed ID: 23947011 [TBL] [Abstract][Full Text] [Related]
3. New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Aghemo A; De Francesco R Hepatology; 2013 Jul; 58(1):428-38. PubMed ID: 23467911 [TBL] [Abstract][Full Text] [Related]
4. Current race in the development of DAAs (direct-acting antivirals) against HCV. De Clercq E Biochem Pharmacol; 2014 Jun; 89(4):441-52. PubMed ID: 24735613 [TBL] [Abstract][Full Text] [Related]
5. Hepatitis C virus resistance to protease inhibitors. Halfon P; Locarnini S J Hepatol; 2011 Jul; 55(1):192-206. PubMed ID: 21284949 [TBL] [Abstract][Full Text] [Related]
8. Direct-acting and host-targeting HCV inhibitors: current and future directions. Chatel-Chaix L; Germain MA; Götte M; Lamarre D Curr Opin Virol; 2012 Oct; 2(5):588-98. PubMed ID: 22959589 [TBL] [Abstract][Full Text] [Related]
9. Resistance to HCV nucleoside analogue inhibitors of hepatitis C virus RNA-dependent RNA polymerase. Najera I Curr Opin Virol; 2013 Oct; 3(5):508-13. PubMed ID: 24070806 [TBL] [Abstract][Full Text] [Related]
10. Structure-guided design affirms inhibitors of hepatitis C virus p7 as a viable class of antivirals targeting virion release. Foster TL; Thompson GS; Kalverda AP; Kankanala J; Bentham M; Wetherill LF; Thompson J; Barker AM; Clarke D; Noerenberg M; Pearson AR; Rowlands DJ; Homans SW; Harris M; Foster R; Griffin S Hepatology; 2014 Feb; 59(2):408-22. PubMed ID: 24022996 [TBL] [Abstract][Full Text] [Related]
11. Future treatment of chronic hepatitis C with direct acting antivirals: is resistance important? Halfon P; Sarrazin C Liver Int; 2012 Feb; 32 Suppl 1():79-87. PubMed ID: 22212577 [TBL] [Abstract][Full Text] [Related]
12. [RESISTANCE OF HCV TO NEW DIRECT ACTING ANTIVIRALS]. Gozlan Y; Mendelson E; Ben-Ari Z; Mor O Harefuah; 2015 Nov; 154(11):684-7, 743. PubMed ID: 26821497 [TBL] [Abstract][Full Text] [Related]
13. The race for interferon-free HCV therapies: a snapshot by the spring of 2012. De Clercq E Rev Med Virol; 2012 Nov; 22(6):392-411. PubMed ID: 22936636 [TBL] [Abstract][Full Text] [Related]
15. Clinical relevance of HCV antiviral drug resistance. Welsch C; Zeuzem S Curr Opin Virol; 2012 Oct; 2(5):651-5. PubMed ID: 23006585 [TBL] [Abstract][Full Text] [Related]
16. Review of direct-acting antiviral agents for the treatment of chronic hepatitis C. Shah N; Pierce T; Kowdley KV Expert Opin Investig Drugs; 2013 Sep; 22(9):1107-21. PubMed ID: 23735127 [TBL] [Abstract][Full Text] [Related]
17. Meet the Classes of Directly Acting Antiviral Agents: Strengths and Weaknesses. Chacko KR; Gaglio PJ Clin Liver Dis; 2015 Nov; 19(4):605-17, v. PubMed ID: 26466650 [TBL] [Abstract][Full Text] [Related]
18. Recent Advancement of Direct-acting Antiviral Agents (DAAs) in Hepatitis C Therapy. Das D; Pandya M Mini Rev Med Chem; 2018; 18(7):584-596. PubMed ID: 28901852 [TBL] [Abstract][Full Text] [Related]
19. Protease Inhibitors Block Multiple Functions of the NS3/4A Protease-Helicase during the Hepatitis C Virus Life Cycle. McGivern DR; Masaki T; Lovell W; Hamlett C; Saalau-Bethell S; Graham B J Virol; 2015 May; 89(10):5362-70. PubMed ID: 25740995 [TBL] [Abstract][Full Text] [Related]
20. Changing the face of hepatitis C management - the design and development of sofosbuvir. Noell BC; Besur SV; deLemos AS Drug Des Devel Ther; 2015; 9():2367-74. PubMed ID: 25987834 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]